European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

The American Journal of Nephrology, published by KARGER, stands as a prestigious platform for the dissemination of high-quality research in the field of nephrology, boasting an impressive Q1 ranking in its category as of 2023. With its ISSN 0250-8095 and E-ISSN 1421-9670, the journal has been committed to advancing knowledge in kidney diseases since its inception in 1981. It serves as an essential resource for researchers, clinicians, and students alike, featuring original articles, reviews, and case reports that contribute to the understanding and treatment of renal conditions. Despite not being an open-access journal, the American Journal of Nephrology ensures a rigorous peer-review process to maintain its high academic standards, making it a vital source of information for the nephrology community worldwide. By providing insights into emerging trends and breakthroughs in kidney health, the journal continues to play a crucial role in shaping the future of nephrology research.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Nephrologie & Therapeutique is a distinguished peer-reviewed journal published by JOHN LIBBEY EUROTEXT LTD, dedicated to the field of nephrology. Since its inception in 2005, this journal has been pivotal in disseminating high-quality research in the areas of kidney disease, renal therapies, and nephrological advancements, and it continues to serve as an essential resource for professionals, researchers, and students alike. With an ISSN of 1769-7255 and an E-ISSN of 1872-9177, the journal is indexed in Scopus and is currently ranked in the third quartile (Q3) within the nephrology category, showing significant contributions to the discipline, despite its current ranking of 64 out of 81. Although Nephrologie & Therapeutique does not operate under an open access model, it nevertheless provides valuable insights and updates on the latest findings and practices in nephrology, making it an important platform for academic discourse in this field. The journal's commitment to advancing knowledge and fostering interdisciplinary dialogue underscores its role as a key player in shaping future research and clinical practices in nephrology.

Kidney International Reports, published by ELSEVIER SCIENCE INC, stands as a premier open-access journal in the realm of nephrology, having established itself since its inception in 2016. This scholarly platform, with an ISSN of 2468-0249, is dedicated to presenting high-quality research and critical reviews that advance our understanding of kidney health and disease. With a remarkable Q1 ranking in nephrology and a notable position within the top 10 of Scopus rankings for this specialty, the journal is a pivotal resource for researchers, healthcare professionals, and students alike. Featuring a broad scope of topics from clinical nephrology to innovative treatment strategies, Kidney International Reports ensures accessibility to the latest findings through its open access model, making it instrumental in promoting knowledge sharing and collaboration across the global nephrology community. The journal's commitment to excellence not only enhances the visibility of research but also fosters the development of effective treatments and therapies for kidney diseases.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

Revista Colombiana de Cancerologia is a premier journal dedicated to advancing the field of oncology in Colombia and beyond. Published by the Instituto Nacional de Cancerología, this journal serves as a vital platform for the dissemination of high-quality research, comprehensive reviews, and innovative methodologies pertinent to cancer research and treatment. With an ISSN of 0123-9015 and E-ISSN 2346-0199, it aims to engage a diverse audience, including researchers, healthcare professionals, and students, fostering collaboration and knowledge sharing within the oncology community. Although specific metrics such as impact factors and H-index are currently unavailable, the journal is committed to maintaining high academic standards and encouraging open access to vital oncological insights. The Revista Colombiana de Cancerologia is positioned as an essential resource for those interested in the latest advancements in cancer care, prevention, and research methodologies, making significant contributions to the understanding and management of cancer.

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.